Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
NCT07636824Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and tegafur in extrahepatic cholangiocarcinoma (eCCA) and gallbladder carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Recurrence-Free Survival at 2 years. Started Jun 2026; status: recruiting.
02
Drugs
capecitabinetegafur
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT07636824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636824.